Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

The vaccine, mFlusiva, is 27 percent more effective at preventing flu in this age group than standard-dose vaccines, ...

Moderna shares declined as investors locked in profits following recent rallies. Analysts expressed skepticism regarding ...

- Analysts highlight forced buying's limited sustainability, with Citi cutting to Sell ($80 target) and Barclays BCS-2.98% at $125, both below current price. - Implied volatility (87%) reflects market ...

Open a VIP account (an enterprise account with priority handling, 24/7 dedicated customer care, unlimited usage/users, help on formatting, standards, rules, regulations, policy compliance, etc., and ...

Tempus is doubling down on its work with Moderna and Merck under a new multiyear collaboration to support the potential commercialization of a cancer drug. The healthcare-technology company said ...

Moderna will join the Nasdaq 100 from Oct. 9, replacing Warner Bros Discovery, Nasdaq has announced. The vaccine maker has ...

• Moderna joins the Nasdaq-100 Index, driving institutional portfolio rebalancing and share accumulation. • Optimism for the Merck partnershiped oncology pipeline boosts long-term investor market ...